Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vascular Biogenics Ltd.    VBLT   IL0011327454

VASCULAR BIOGENICS LTD.

(VBLT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
2.5(c) 2.5(c) 2.5(c) 2.56(c) 2.69(c) Last
546 277 635 412 283 139 434 551 3 426 455 Volume
+3.73% 0.00% 0.00% +2.40% +5.08% Change
More quotes
Financials (USD)
Sales 2020 0,94 M - -
Net income 2020 -23,1 M - -
Net Debt 2020 - - -
P/E ratio 2020 -5,08x
Yield 2020 -
Sales 2021 0,91 M - -
Net income 2021 -27,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,89x
Yield 2021 -
Capitalization 130 M 130 M -
Capi. / Sales 2020 138x
Capi. / Sales 2021 143x
Nbr of Employees 38
Free-Float 77,1%
More Financials
Company
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an... 
More about the company
Notations Surperformance© of Vascular Biogenics Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about VASCULAR BIOGENICS LTD.
01/15SECTOR UPDATE : Health Care Stocks Flat To Lower Pre-Bell Friday
MT
01/15VASCULAR BIOGENICS : Signs $20 Million Ordinary Share Purchase Agreement With As..
MT
01/15VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 M..
GL
01/13VASCULAR BIOGENICS : Oppenheimer Adjusts Vascular Biogenics PT to $5 From $2.50,..
MT
01/05VASCULAR BIOGENICS : Company Presentation January 2021
PU
2020VASCULAR BIOGENICS : Enrolls First Patient in Europe for Ovarian Cancer Drug Tri..
MT
2020VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
GL
2020VBL Therapeutics Announces Insider Buying
GL
2020VASCULAR BIOGENICS : Company Presentation November 2020
PU
2020VBL Therapeutics Reports Third Quarter 2020 Financial Results and Provides Co..
GL
2020VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conferen..
GL
2020VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 1..
GL
2020VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platf..
GL
2020VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Boar..
GL
2020Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodi..
GL
More news
News in other languages on VASCULAR BIOGENICS LTD.
2019VASCULAR BIOGENICS LTD : publication des résultats annuels
2019VASCULAR BIOGENICS LTD : Veröffentlichung des Jahresergebnisses
2016VASCULAR BIOGENICS LTD : publication des résultats semestriels
2016VASCULAR BIOGENICS LTD : Veröffentlichung des Halbjahresergebnisses
2016VASCULAR BIOGENICS LTD : publication des résultats annuels
More news
Analyst Recommendations on VASCULAR BIOGENICS LTD.
More recommendations
Chart VASCULAR BIOGENICS LTD.
Duration : Period :
Vascular Biogenics Ltd. Technical Analysis Chart | VBLT | IL0011327454 | MarketScreener
Technical analysis trends VASCULAR BIOGENICS LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 4,50 $
Last Close Price 2,69 $
Spread / Highest target 85,9%
Spread / Average Target 67,3%
Spread / Lowest Target 11,5%
EPS Revisions
Managers and Directors
NameTitle
Dror Harats Chief Executive Officer & Director
Bennett M. Shapiro Chairman
Eyal Breitbart Vice President-Research & Operations
Erez Feige Vice President-Business Operations
Amos Ron Chief Financial Officer & Secretary
Sector and Competitors
1st jan.Capitalization (M$)
VASCULAR BIOGENICS LTD.42.33%130
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148